Clinical trials: Prostate Cancer With Intermediate Risk
Prostate Cancer
Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer
The purpose of this study is to evaluate the safety of a new drug- sorafenib, which is to be administered at the same time as standard treatment, which includes hormonal therapy and external beam radiotherapy.
- Trial name
- NCT00924807
- Testing
- Leuprolide acetate, Bicalutamide, Sorafenib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Beth Israel Medical Center
Prostate Cancer
External-Beam Radiation Therapy Plus Implanted Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other sources to damage tumor cells. Giving radiation therapy in different ways may kill more tumor cells.
- Trial name
- NCT00006365
- Testing
- brachytherapy, iodine I 125, radiation therapy
- Where
- 254 sites in United States, Canada
- Volunteers
- 138 people
- Sponsor
- Radiation Therapy Oncology Group
Patient With Prostate Cancer
Validation of Radioisotope Guided Lymphadenectomy for Loco-regional Staging in Patients With Intermediate or High-risk Prostate Cancer
The diagnosis of a ganglionic infringement(achievement) at a patient reached (affected) by a prostate cancer is a factor(mailman) of bad forecast.
- Trial name
- SENTINELLE (NCT02732392)
- Testing
- standard lymphadenectomy, lymphadenectomy radio-isotope method
- Where
- France
- Volunteers
- 177 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Prostate Cancer (Adenocarcinoma)
Optimal Duration of Hormonal Therapy for Unfavorable Intermediate-risk Prostate Cancer Patients: 6 Versus 12 Months.
Patients with unfavorable intermediate-risk prostate cancer will be randomized between 6 versus 12 months of hormone therapy with radiation therapy.
- Trial name
- PCS-XII (NCT06855589)
- Testing
- 6 months of Eligard, 12 months of Eligard, prostate SBRT or prostate brachytherapy with radiation therapy
- Where
- 5 sites in Canada
- Volunteers
- 400 people
- Sponsor
- Charles LeMoyne Hospital
Prostate Cancer
Feasibility Trial Of Image Guided External Beam Radiotherapy With Or Without High Dose Rate Brachytherapy Boost In Men With Intermediate-Risk Prostate Cancer
This research is being done because investigators involved in this study would like to compare image guided external beam radiation therapy (IGRT) to IGRT plus HDR brachytherapy boost to see which treatment is better and what the…
- Trial name
- NCT01982786
- Testing
- Image guided external beam radiotherapy with or without brachytherapy boost, Brachytherapy
- Where
- 9 sites in Canada
- Volunteers
- 57 people
- Sponsor
- Canadian Cancer Trials Group
Prostate Cancer
Triptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as triptorelin and flutamide, may stop the adrenal glands from making androgens. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT00104741
- Testing
- flutamide, triptorelin, radiation therapy
- Where
- 31 sites in France
- Volunteers
- 378 people
- Sponsor
- UNICANCER